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Abstract
Background Medication-related problems (MRPs) are the un-
desirable effects of pharmacotherapy that can potentially lead
to harm. The epidemiology of MRPs in paediatric renal pa-
tients is unknown. We aimed to characterise MRPs in this
population at two tertiary care hospitals in the UK.
Methods Prescription charts for children (≤18 years) were
reviewed to identify MRPs, and characterised using a specific
proforma with a standard operational definition. MRP predic-
tors were evaluated by logistic regression and severity was
assessed using a validated scale.
Results Two hundred and sixty-seven MRPs were identified
from 266 prescription chart reviews. The incidence was
51.2 % (203 MRPs, 166 charts; 95 % CI 43.2–60.6 %) of
hospitalised patients and 32% (64MRPs, 100 charts; 95% CI
22.9–41.1 %) in outpatients. The number of prescribed med-
ications was the only independent predictor during inpatient
treatment (OR 1.06, 95 % CI 1.02–1.10, p=0.002) with no
significant predictors identified at outpatient clinics. The se-
verity level of the MRPs was minor: 53.9 %, (144 out of 267);
or moderate: 46.1 %, (123 out of 267). Sub-optimal drug
effect was the predominant MRP (inpatient: 68 %; outpatient:
39 %). Prescribing error and patients' medicine-taking behav-
iour were the main contributory factors. The majority of the
MRPs in the inpatient setting were resolved.
Conclusion Many factors are associated with MRPs in chil-
dren; the associations are cumulative and interdependent.
Investment in preventive strategies and extending the support
from the acute health care setting into the community are
invaluable for optimising pharmacotherapy.
Keywords Paediatric nephrology .Medication safety .
Prescribing errors . Pharmacotherapy . Drug-related problems
N. Ibrahim : I. C. K. Wong :Y. Jani
Centre for Paediatric Pharmacy Research, School of Pharmacy,
University College London, London, UK
N. Ibrahim
Pharmacy Department, Paediatric Institute, General Hospital Kuala
Lumpur, 50586 Jalan Pahang, Kuala Lumpur, Malaysia
I. C. K. Wong
Centre for Safe Medication Practice and Research, Department of
Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine,
University of Hong Kong, Hong Kong, China
S. Tomlin
Pharmacy Department, Evelina London Children’s Hospital, Guy’s
and St. Thomas’ Hospital NHS Foundation Trust, King’s Health
Partners, London, UK
M. D. Sinha
Department of Paediatric Nephrology, Evelina London Children’s
Hospital, Guy’s and St. Thomas’ Hospital NHS Foundation Trust,
King’s Health Partners, London, UK
L. Rees
Department of Nephrology, Great Ormond Street Hospital NHS
Foundation Trust, London, UK
Y. Jani
Pharmacy Department, University College London Hospital NHS
Foundation Trust, London, UK
I. C. K. Wong (*)
Li Ka Shing Faculty of Medicine, University of Hong Kong, 2/F, 21
Sassoon Road, Laboratory Block, Faculty of Medicine Building,
Hong Kong, China
e-mail: wongick@hku.hk
Pediatr Nephrol (2015) 30:623–633
DOI 10.1007/s00467-014-2982-5
Introduction
Medications are prescribed with the intention of benefiting the
patient. However, the use of medications can be undesirable
and potentially lead to harm. These undesirable effects are
known as medication-related problems (MRPs). A MRP is
defined as an event involving pharmacotherapy that interferes
with the patient experiencing an optimal outcome of medical
care [1]. Medications for patients with kidney disease are
specialised and complex. In those with chronic kidney disease
(CKD), the relevance of optimal pharmacotherapy manage-
ment is even more critical, thus putting this group of children
at risk of developing MRPs. The National Kidney
Foundation/Kidney Dialysis Outcome Quality Indicator
(NKF/KDOQI) guideline recommends that a medication re-
view should be performed for children and adolescents at all
visits for the prevention of MRPs such as inappropriate doses,
inadequate therapeutic monitoring and potentially adverse
drug effects on the kidney or disease complications [2].
Medication-related problems are common in children: re-
cent studies have reported that the incidence in the UK is
39.4 % in hospitalised children [3] and 2.7 % of children on
medications were admitted to the emergency departments in
the UK [4]. However, these studies did not include paediatric
renal patients. Current management of MRPs in this group is
based on what has been learned from adult studies [5], which
may be unrepresentative of the paediatric population.We have
previously reported on the paucity of data on the epidemiol-
ogy of MRPs in children with kidney disease and suggested
further studies for proactive strategies inmedication safety [5].
This current study aimed to determine the characteristics of
MRPs and potential risk factors for their occurrence in chil-
dren with kidney disease at the tertiary renal centres.
Materials and methods
Setting and study subjects
Two observational cohort studies were conducted at the renal
unit of the Evelina London Children’s Hospital (ELCH) and
Great Ormond Street Hospital for Children (GOSH). Study 1
was conducted in an inpatient setting at ELCH and GOSH and
study 2 was conducted in the renal outpatient clinics at ELCH.
Approval was obtained from the Research Ethics Committee,
UK. Both hospitals are two of the largest children’s renal
centres and provide tertiary care to approximately 40 % of
children requiring renal replacement therapy (RRT) in the UK
[6]. The renal units are led by teams of paediatric nephrolo-
gists, supported by a team of healthcare professionals includ-
ing specialist renal nurses, renal pharmacists and nutritionists.
The cases seen in both units include all aspects of paediatric
renal disease, including RRT.
Study 1, inpatient setting The clinical team in both hospitals
conducted daily a full patient review and clinical rounds. Clinical
pharmacy practice is established as standard care in the inpatient
setting; this enabled the pharmacists to review prescription charts
as a standard clinical routine. Prescription chart review was
conducted using paper documentation in ELCH and from an
electronic prescribing system (ePS) in GOSH.
Study 2, outpatient clinic setting The renal outpatient clinics
in ELCH operate daily on weekdays. Patients’ clinic notes and
medication lists were documented on a multidisciplinary elec-
tronic medical record (eMR). Unlike the inpatient setting,
clinical pharmacy practice is not part of the standard care
and thus, prescription chart review was not routine for all
patients attending the clinic.
The inclusion criteria for both studies were the same: all
children aged 18 years and younger, who had received at least
one long-term (non-acute) medication. Additionally, children
who were included in the inpatient study had to have been
hospitalised for at least 24 h.
Data collection
Study 1, inpatient study Data were collected for hospitalised
patients at ELCH and GOSH from 1 December 2011 to 1
September 2012. At each site, one pharmacist was responsible
for the detection ofMRPs using a structured tool and prospective
prescription chart reviewmethod during routine clinical practice.
Recommendations on the resolution of theMRPswere discussed
with the clinical team during clinical rounds; this method has
been used in previous paediatric MRP studies [3, 4, 7, 8].
Study 2, outpatient clinic study Data were collected at ELCH
from 18 February to 18 September 2013. As clinical pharma-
cy practice was not a standard care at the outpatient clinic and
in order to ensure the consistency of data, one researcher was
responsible for identifying MRPs from the eMR, using a
structured approach. In the event that an MRP with potential
harm to the patient was identified, the researcher would alert
the clinical team.
The two pharmacists who were involved in collecting the
data in the inpatient setting had received similar professional
training and each had more than 10 years’ experience in
tertiary paediatric renal pharmacy practice. The researcher is
also a qualified pharmacist trained in renal pharmacy, but not
working in the capacity of a pharmacist within the Trusts. The
pharmacists and the researcher received training on the defi-
nition and characteristics of MRPs before initiation of the
research. All MRPs were recorded onto a proforma using a
standard code and operational definition (Appendix 1). All
prescribed medications associated with MRPs were classified
according to the World Health Organisation Anatomical
Therapeutic Chemical (WHO-ATC) system.
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All different medications prescribed throughout the pa-
tients’ hospital stay (in study 1) and all medications listed in
the patient’s clinic notes (in study 2) were recorded.
Incidence and risk factors
The incidence of MRPs in the study cohort was defined
as the number of patients with at least one MRP iden-
tified during prescription chart review, divided by the
total number of patients reviewed multiplied by 100.
For MRP incidence and risk factor calculations, only
the first event of MRP identified during review was
considered for investigating the association between
MRP incidence and potential risk factors.
Analysis of MRP severity
Similar to previously published paediatric MRP studies
[3, 9] this project adopted a validated severity scoring tool
for medication errors [10]. The MRPs were independently
assessed by four health care professionals comprising a
paediatric nephrology consultant, paediatric consultant phar-
macist, medication safety pharmacist and a specialist renal
nurse. The MRPs were assessed in terms of clinical signif-
icance, with scores ranging from 0 to 10 using a visual
analogue scale, where 0 represented a case with no poten-
tial harm and 10 represented a case that would result in
death. An MRP was considered minor (unlikely to have
any adverse effects) if the score was < 3, moderate (likely
to cause some adverse effects or interfere with therapeutic
goals) if the score was between 3 and 7, or severe (likely
to cause lasting impairment or death) if the score was > 7.
The mean severity score (μScore) from all assessors was
the final score assigned to each MRP.
Classification of medications and MRPs
The medications that were associated with MRPs were clas-
sified according to the WHO-ATC system. The identified
MRPs were documented in a specified proforma adapted from
the Pharmaceutical Care Network Europe (PCNE) MRP
Classification Scheme [11]. The operational definition of the
types and contributory factors of MRPs is available in
Appendix 1.
MRP resolution
Prescription review was not standard clinical practice in the
outpatient clinic; thus, corrective measures and resolution
rates could only feasibly be evaluated for MRPs identified
during study 1, in the inpatient setting. AMRP was defined as
“solved” on occasions when actions were taken before
causing any harm to patients or actions were taken to solve
an ongoing MRP.
Statistics
Data were analysed using the Statistical Package for Social
Science (SPSS) version 21 and presented as percentages (%),
mean with standard deviation (SD) or median with interquar-
tile range (IQR 1–3) and odds ratios (OR) with 95 % confi-
dence interval (CI). For the descriptive analysis of patient and
MRP characteristics, Chi-squared (χ2), Kruskal–Wallis, Rank
and Mann–Whitney tests were used as appropriate. In all
statistical tests p values of less than 0.05 were considered
statistically significant.
Multivariate logistic regressionwas performed to assess the
impact of predictors on the likelihood MRPs would occur
among the study population. The regression worked around
one binary outcome (at least one MRP identified: yes/no) and
six independent variables: age (years), gender, number of med-
ications prescribed (Rx) and types of RRT (dialysis, post-
transplant and non-RRT). The variable Rx refers to the number
of different medications that were prescribed during the data
collection period. Additional independent variables analysed in
the inpatient study were length of hospital stay in days (LOS)
and types of ward admission (elective or non-elective). Elective
admission refers to scheduled admission to the ward for inpa-
tient treatment or procedure. Non-elective admission refers to
cases transferred from other wards or hospitals for continuation
of care. The factors that were analysed in the regression anal-
yses included those found to be relevant in the literature and of
pathophysiological significance [3, 12–14].
Results
A total of 227 patients fulfilled the inclusion criteria and 267
MRPs were identified (Inpatient, n=127 patients, 203 MRPs
(mean 1.2MRPs per patient (SD 2);Outpatient, n=100 patients,
64 MRPs (mean 0.6 MRPs per patient (SD 1.4)). All MRPs
were included for analyses. The incidence of MRPs in the
inpatient cohort was 19.2 % higher than the Outpatient cohort
(51.2 %, 95 % CI 43.2 – 60.6 % vs. 32 %, 95 % CI 22.9 –
41.1 %, p=0.04). The study results are summarised in Table 1.
Characteristics of the study population
The majority of patients were male. Inpatients were younger
than the outpatient cohort (inpatient: median 6.6 years [IQR 1.8–
12.5]; outpatient: median 9.7 (IQR 5.7–14.2), p=<0.001).
Inpatients who developed MRPs, compared with those who
did not, had a longer length of hospital stay (median 9 vs 4 days,
p<0.001), were on dialysis or had kidney transplant (p=0.001)
Pediatr Nephrol (2015) 30:623–633 625
and more medications prescribed (p<0.001; Table 2). Of
the 127 inpatients, 6 were diagnosed with acute kidney
injury (AKI). Of the 6 AKI cases, 1 was secondary to
sepsis and another was due to the use of radio-contrast
agent. The remaining 4 cases could not be confirmed to
have any association with the use of medications as
they had unknown causes.
Risk factors for MRPs
The number ofmedications prescribed per child was the single
significant predictor for MRPs at the inpatient setting (OR
1.06, 95 % CI 1.02–1.10, p=0.002). The odds ratio of 1.06
indicates that the chance of having anMRP is 6 % higher with
every additional medication. There was a trend toward a
higher prediction of MRPs in patients on dialysis compared
with those not on dialysis, but this finding was not statistically
significant. None of the predictors analysed here was statisti-
cally significant for the outpatient cohort.
MRP severity assessment
The 64 MRPs identified from the outpatient clinic scored
higher on the severity scale compared with the 203 MRPs
identified in the inpatient setting (μScore range: outpatient
clinic: 2.1–5.8; inpatient 0.1–6.8).
Medications associated with MRPs
The groups of medicines most often associated with MRPs
were those used for “alimentary tract and metabolism”, “sys-
temic anti-infective” and “blood and blood forming organs”
(Table 3). MRPs in inpatients were commonly reported with
the use of nystatin 7.9 %, 16 out of 203), paracetamol (7.4 %,
Table 1 Summary of results for study 1 (inpatient setting) and study 2 (outpatient renal clinic)
Study 1: inpatient setting Study 2: outpatient renal clinic
Number of patients recruited 127 100
Gender (male) 53.5 %, n=68 55 %, n=55
Median age (IQR) of children with MRPs 5.0 (1.3–11.9) 10.3 (5.2–13.8)
MRP incidence per patient reviewed (95 % CI) 51.2 % (43.2–60.6) 32 % (22.9–41.1)
Significant risk factor for the occurrence of MRPs The numbers of medicine prescribed per child None identified
Total MRPs identified (n=227) 203 MRPs 64 MRPs
MRP severity level Minor 68 %, 138 out of 203 Minor 9.4 %, 6 out of 64
Moderate 32 %, 65 out of 203 Moderate 90.6 %, 58 out of 64
Predominant MRPs Sub-optimal drug effect 21.7 %, 44 out of 203 Sub-optimal drug effect 39.1 %, 25 out of 64
MRP resolution rate Solved DRPs 96 %, 195 out of 203 Not evaluated
MRP medication-related problem, DRP drug-related problem
Table 2 Patient demographic characteristics
Inpatients (N=127) Outpatient clinic (N=100)
MRPsb No MRPs p value MRPsb No MRPs p value
Gender 0.44 0.76
Male 37 (29.1) 31 (24.4) 17 (17.0) 38 (45.0)
Female 28 (22.0) 31 (24.4) 15 (15.0) 30 (37.0)
Median age 5.0 (1.3–11.9) 8.1 (2.1–13.2) 0.22 10.3 (5.2–13.8) 9.3 (5.7–14.4) 0.85
Median length of hospital stay (days) 9 (4–20) 4 (3–7) <0.001 NA NA NA
Type of ward admission 0.45 NA NA NA
Elective 41 (32.3) 35 (27.6)
Non-elective 24 (18.9) 27 (21.3)
Renal replacement therapy 0.001 0.38
Dialysis 20 (15.7) 8 (6.3) 13 (13.0) 22 (22.0)
Kidney transplant 18 (14.2) 11 (8.7) 7 (7.0) 12 (12.0)
No RRT 27 (21.3) 43 (33.9) 12 (12.0) 34 (34.0)
Median number of medicines prescribed per childa 28 (13–15) 10 (7–19) <0.001 5 (3–7) 5 (3–7) 0.55
Data are median (IQR 1–3) or frequency (% of N) RRT renal replacement therapy, MRP medication-related problem
aMedian number of medicines prescribed throughout hospital stay
bAt least one MRP identified during prescription review
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15 out of 203) and ranitidine (5.4 %, 11 out of 203), whereas
MRPs in outpatients were associated with prednisolone
(15.6 %, 10 out of 64), sodium bicarbonate (9.4 %, 6 out of
64) and alfacalcidol (7.8 %, 5 out of 64).
The types and contributory factors of MRPs
Sub-optimal drug effect was the predominant MRP identified in
both clinical settings; however, their contributory factors were
distinct. The characteristics of theMRPs are presented in Table 4.
Inpatient setting
The predominant MRPs were “sub-optimal drug effect”
(21.7 %, 44 out of 203), “unnecessary treatment” (20.2 %,
41 out of 203) and “toxic adverse reaction” (19.2 %, 39 out of
203). The majority of the MRPs were identified and resolved
before they caused any harm (55.1 %, 112 out of 203).
Prescribing errors in the selection of medications and doses
were the main contributory factors for the occurrence of
MRPs. The following are examples of cases:
MRP1 Valganciclovir 400 mg once a day was prescribed
post-transplant; the dose should have been optimised
to 500 mg according to renal function (μScore 2.8).
MRP2 50 mcg stat dose of intravenous prazosin was pre-
scribed to a neonate, but 500 mcg was administered
(μScore 5.5).
MRP3 Intravenous gentamicin for septicaemia was prescribed
for a patient with acute renal dysfunction; daily doses
of gentamicin were continued for 2 weeks without the
serum drug level being monitored (μScore 7.4).
Outpatient clinic
The predominant MRPs were “sub-optimal drug effect”
(39.1 %, 25 out of 64), “drug administration problems”
Table 3 Medications associated with MRPs
WHO ATC code Study 1: inpatient
n (% of 203)
Study 2: outpatient clinics
n (% of 64)
(A) Alimentary tract and metabolisma
Nystatin, ranitidine, alfacalcidol, calcium carbonateb 52 (25.6) 12 (18.8)
(B) Blood and blood-forming organsa
Acetylsalicylic acid, erythropoietin, electrolytes (e.g., sodium bicarbonate/chloride)b 27 (13.3) 15 (23.4)
(C) Cardiovascular system
Enalapril, furosemide, nifedipineb 10 (4.9) 2 (3.1)
(D) Dermatological
Fusidic acid, gentamicin, mupirocinb 4 (2) 0
(G) Genitourinary system and sex hormones
Oxybutininb 2 (1) 0
(H) Systemic hormonal preparations, excluding sex hormones
Steroids-based products (e.g., prednisolone, methylprednisolone), octreotide, levothyroxineb 15 (7.4) 10 (15.6)
(J) Anti-infectives for systemic usea
Penicillins, cephalosporins, vaccinesb 49 (24.1) 11 (17.2)
(L) Antineoplastic and immunomodulating agents
Tacrolimus, mycophenolic acid, ciclosporine, cyclophosphamideb 11 (5.4) 10 (15.6)
(M) Musculo-skeletal system
Pamidronic acidb 1 (0.5) 0
(N) Nervous system
Paracetamol, morphine, codeine 23 (11.3) 3 (4.7)
(P) Antiparasitic products, insecticides and repellents
Levimasoleb 1 (0.5) 1 (1.6)
(R) Respiratory system
Cyclizine, fluticasone, cetrizineb 7 (3.4) 0
(S) Sensory organs
Dexamethasone and anti-infectivesb 1 (0.5) 0
(V) Various
Polystyrene sulfonateb 1 (0.5) 0
WHO ATCWorld Health Organisation Anatomical Therapeutic Chemical system
a The predominant groups
b The most common medicines reported in each group
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(29.7 %, 19 out of 64) and “non-allergic adverse drug events”
(17.2 %, 11 out of 64). The contributory factors for MRPs
were associated with patients’medicine-taking behaviour and
other factors (e.g. unwanted side effects and dependency on
feeding tubes for the administration of medications). The
following are examples of cases:
MRP1 A patient with vesicoureteric reflux was dependent
on the enteral feeding tube. The family struggled to
administer iron supplement (and other oral medica-
tions) as prescribed (μScore 2.1).
MRP2 Activated vitamin D for the prevention of hyperpara-
thyroidism was prescribed to a patient with advanced
kidney failure. The family had problems in obtaining
a continuous supply in the community setting
(μScore 3.9).
MRP3 A patient had on-going proteinuria, but had been
non-compliant with treatment for the past 6 months
(μScore 5.8).
MRP resolution
Of the 203 MRPs identified from the inpatient setting, 96 %
(195 out of 203) were resolved as a result of multidisciplinary
care. Most MRPs were resolved by changes to the medication
selection, doses and dosing frequency. The pharmacists
played an important role in providing consultations on
medication regimens and 99.5 % of the recommendations
(227 out of 228) were accepted by the clinical team.
Discussion
To our knowledge this is the first study investigating MRPs
systematically in children with kidney disease in the UK. We
observed that whilst not all predictors for MRPs were signif-
icant, our results are particularly important, not only in under-
standing the characteristics of MRPs in this population, but
also in enabling the development of preventive strategies in
clinical practice.
It is worth discussing further the differences in the demo-
graphic characteristics between study subjects in the inpatient
and outpatient setting in the current research. Even though all
subjects were children with kidney disease, the majority of those
seen at the outpatient clinics were in the pre-dialysis stage. Our
study shows that those receiving inpatient treatments require
three times the numbers of medications than the outpatient
cohort (median 17 vs 5 medications per child). Children receiv-
ing inpatient treatment were by definition more ill and this was
likely due to more advanced disease or complications of RRT.
Many studies in adults with CKD have previously demonstrated
that patients at the late stage of CKD and on RRT require more
complex pharmacotherapy and are exposed to increased chances
of MRPs [15, 16]. There was an association between the
Table 4 Types of medication-related problems (MRPs) identified in the study cohort by the main and sub-categoriesa
MRP characteristics Study 1, inpatient setting Study 2, outpatient clinic
n (%) n (%)
Types of MRPs P1.1 No effect of drug treatment 3/203 (1.5) 0/64
P1.2 Sub-optimal effect 44/203 (21.7) 25/64 (39.1)
P1.4 Untreated indication 20/203 (9.9) 1/64 (1.6)
P2.1 Non-allergic reaction 22/203 (10.8) 11/64 (17.2)
P2.2 Allergic drug reaction 3/203 (1.5) 1/64 (1.6)
P2.3 Toxic adverse reaction 39/203 (19.2) 2/64 (3.1)
P3.1 Unnecessary treatment 41/203 (20.2) 0/64
P4.1 Patient dissatisfaction 1/203 (0.5) 0/64
P4.2 Drug administration problems 30/203 (14.8) 19/64 (29.7)
P4.3 Delay in treatment 0/203 5/64 (7.8)
Contributory factors for MRPsb C1 Inappropriate drug selection 72/399 (18.0) 3/73 (4.1)
C2 Inappropriate drug form 7/399 (1.8) 0/73
C3 Inappropriate drug dosage 97/399 (24.3) 4/73 (5.5)
C4 Inappropriate treatment duration 15/399 (3.8) 0/73
C5 Medication errors 181/399 (45.4) 1/73 (1.4)
C6 Drug supply problems 0/399 8/73 (11.0)
C7 Patient factors 1/399 (0.3) 31/73 (42.5)
C8 Other factors 26/399 (6.5) 26/73 (35.6)
a The operational definition for the types and contributory factors of MRPs is available in Appendix 1
b Full description of the contributory factors for MRPs is available in Appendix 2.
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occurrence of MRP and the length of hospital stay; however,
further research is required to assess causality.
Interestingly, despite having more serious clinical condi-
tions in hospitalised patients, the majority of MRPs were
scored as minor (68 %,138 out of 203) compared with the
MRPs identified at the outpatient clinic in which 90.6 % (58
out of 64) were scored as moderate. The possible reason for
this lies in the difference of care between tertiary care centres
and the community. Problems in the use of medications oc-
curring in inpatients are “active errors” [17]. Similar to previ-
ous paediatric medication error research [7, 8, 18, 19] the
majority of the “active errors” in the current study were caused
by prescribing errors. These errors could rapidly be rectified
by the healthcare professionals and were less likely to cause
harm as a result of the interventions. As an example, sub-
optimal tacrolimus dose in the management of post-kidney
transplantation on the ward could be adjusted from post-12-h
tacrolimus serum drug levels. Changes to drug regimens are
directly monitored and patients receiving inpatient treatment
are likely to adhere to the prescribed therapy.
In contrast, drug problems occurring in the community are
“latent errors”, most of which are caused by exogenous factors
that are beyond the control of healthcare professionals [20].
An example of exogenous factors in the current research was
difficulties in obtaining unlicensed and off-label medications
from the community.
The types of medications associated with MRPs in our
study portrayed the common prescribing pattern in the paedi-
atric population [3, 21, 22]. However, medicines of the “blood
and blood forming agents” are unique to MRPs in renal
patients [12, 13, 23, 24]. The medications that were more
often associated with MRPs were also those more often pre-
scribed. It is also important to note that there are limited data
available for the safe and effective doses of most medications
used in children [3, 25]. This may contributed to the observed
tendency for higher numbers of adverse drug events and other
MRPs in this cohort.
It is a challenging task to determine an optimal and safe
dose for children with kidney disease owing to their physiol-
ogy and the altered pharmacokinetic properties of medications
[21, 26]. The management of MRPs should be a shared
responsibility of all healthcare providers. The MRP classifi-
cations and the MRP screening tool used in the present re-
search could also be integrated into the physician’s practice.
Other strategies to reduce the occurrence of MRPs are to
integrate medication reconciliation into patients’ medicine
management program. This program was also recently
highlighted for the care of adult renal patients [27, 28]. In
the UK, a survey among paediatric pharmacists found that
only 34 % had full medication reconciliation in place [29]. A
policy on medication reconciliation on hospital admission and
at discharge, including routine outpatient clinic appointments,
minimises discrepancies in the transfer of information [3].
In the inpatient setting, we found that most MRPs are
largely attributed to prescribing errors. Prescribing errors have
been reported to be preventable; thus, having continuous
awareness programmes on medication safety in paediatrics
remains essential in practice [8, 29–32].
This study reported the rate of MRP occurrence in children
who attended the renal outpatient clinic as less than one MRP
per patient. Nevertheless, the potential harm as a consequence
of these MRPs should not be underestimated. The latent effect
of MRPs in this patient group has not been studied. We
identified cases of poor treatment outcome due to patient
non-adherence. An example of these cases that was highlight-
ed earlier involved a patient with glomerulonephritis leading
to persistent proteinuria.
Difficulties in obtaining medication supplies and poor un-
derstanding about medications among parents and children are
among the factors causing low adherence in CKD [15, 33].
Thus, proper coordination of supplies of medication in the
community is also vitally important and should be anticipated
when unlicensed and/or off-label medications are prescribed for
children. Continuous assessment on changing patients’ cogni-
tive behaviour towards medicines and/or specific clinical out-
comes is also important to empower patients’ involvement in
managing their medications [15, 32, 34]. As caring for children
with kidney disease is a life-long commitment, parents/carers
would benefit from a support system to facilitate them in the
monitoring, prevention and resolution of MRPs.
The strengths of this research lie in usingmultiple approaches
to identifying MRPs, i.e. a prospective chart review in the
inpatient setting and a retrospective chart review in the outpatient
clinic.Wewere aware that the characteristics ofMRPs identified
in both studies reflect the types of methods used. Thus, appro-
priate measures had been taken to minimise the variability of
data that include the use of a structured proformawith a standard
operational definition and training to those involved in collecting
the data. This research included two main referral centres for
paediatric nephrology in London. Thus, the results may not
necessarily be generalisable to other countries with different care
settings.
Conclusion
Medication-related problems in children with kidney disease
necessitate a comprehensive approach to their identification
and resolution. The MRPs in different clinical settings are
unique in their characteristics and levels of severity.
Investment in preventive strategies and extending the support
from the health care setting into the community are invaluable
for optimising pharmacotherapy.
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Appendix 1
Table 5 Coding system for the types and contributory factors of medication-related problems (MRPs) and the operational definition of the modified
Pharmaceutical Care Network (PCNE) MRP classification version 6.2
Main category:
types of MRPs
Codes Sub-categories Operational definition
Drug effect P1 There is a (potential or manifested) problemwith the (lack of) effect of the pharmacotherapy
P1.1 No effect of treatment/therapy failure There is neither improvement nor worsening of the patient’s symptoms
P1.2 Sub-optimal drug effect There is improvement in the patient’s symptoms, but not to the intended target
P1.3 Wrong effect of drug treatment NA
P1.4 Untreated indication There is a symptom (or an anticipated symptom) requiring drug therapy that is not treated
Adverse drug
events
P2 Patient suffers, or will suffer, from an adverse drug event
P2.1 Non-allergic adverse reaction An unintended pharmacological effect from an adverse drug event not suspected as an
allergic reaction (or toxic effect) commonly known to be related to the prescribed drug at
doses normally used for the intended indication (e.g. side effects, intolerable intended
pharmacological effect, e.g. hypotension from the use of antihypertensive agent)
P2.2 Allergic drug reaction An unintended pharmacological effect from an adverse drug event suspected as an allergy
reaction or toxicity, commonly known to be related to the prescribed drug at doses
normally used for the intended indication (e.g. rash and penicillin)
P2.3 Toxic adverse reaction An unintended pharmacological effect related to the drug at doses higher than maximum
dose normally used for the intended indication or adverse effect cause by accumulated
doses
Treatment costs P3 The drug treatment is more expensive than necessary
P3.1 Drug treatment more costly than necessary There is an alternative drug that is cheaper, but is not being used
P3.2 Unnecessary drug treatment The drug that is newly (or previously) prescribed is not required (or no longer required)
Other P4 Other causes not specified above
P4.1 Patient dissatisfied with therapy despite optimal
clinical and economic treatment outcomes
Self-explanatory
P4.2 Drug administration problems Difficulties in administering the appropriate drug at the correct doses to the intended patient
(e.g. paracetamol suppository (540 mg) was prescribed, but the preparation available at
the dispensary is a 240-mg suppository; incomplete instructions of drug administration;
any circumstance that hinders drug administration)
P4.3 Delay in treatment Self-explanatory
Drug selection C1 The cause of the DRP is related to the selection of the drug
C1.1 Inappropriate drug (including contra-indication) The wrong drug is selected or the selected drug is contraindicated for the patient.
Wrong drug is, for example, a patient who is supposed to be on antibiotic A, but is
administered antibiotic B
Contraindicated drug use is, for example, a patient who received a drug to which he had
previously experienced an allergy reaction
C1.2 Inappropriate combination of drugs The selected drug interacts (or has the potential to interact) with another drug(s), food or
device
C1.3 Inappropriate duplication of therapeutic group or
active ingredient
More than one drug of the same therapeutic group or active ingredient is used concurrently
C1.4 Indication for drug treatment not noticed The drug that is indicated to treat a symptom is not used because the existence of the
symptom is not noticed
C1.5 Too many drugs prescribed for an indication More than the necessary drugs are used for treating the same symptom(s)
C1.6 More cost-effective drug available An alternative drug that is cheaper and as effective (or more effective) is not used
C1.7 Synergistic/preventive drug required and not
given
A drug that is required to enhance the existing treatment (synergistic effect) or to prevent the
development of another symptom is not used
C1.8 New indication for drug treatment presented The drug has a new indication that requires a change of dosing regimen (e.g. steroid
maintenance dose in post-transplantation and pulse doses in acute rejection)
Drug form C2 Inappropriate drug form
C2.1 Inappropriate drug form Inappropriate drug form and/or formulation
Dose selection C3 The cause of the DRP is related to the selection of the dosage schedule
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Table 5 (continued)
Main category:
types of MRPs
Codes Sub-categories Operational definition
C3.1 Drug dose too low Dose is insufficient to achieve the therapeutic outcome
C3.2 Drug dose too high Dose is more than necessary to achieve the therapeutic outcome
C3.3 Dosage regimen not frequent enough Dosing frequency is insufficient to achieve the therapeutic outcome
C3.4 Dosage regimen too frequent Dosing frequency is more than necessary to achieve the therapeutic outcome
C3.5 No therapeutic drug monitoring Serum level for a drug with a narrow therapeutic index, not monitored
C3.6 Pharmacokinetic problem requiring dose
adjustment
Changes in renal function requiring dose adjustment
C3.7 Deterioration/Improvement of disease state
requiring dose adjustment
Changes to disease state requiring dose adjustment
C3.8 Dose difficult to measure Prescribed dose difficult to measure
Treatment
duration
C4 The cause of the DRP is related to the duration of therapy
C4.1 Treatment duration too short Treatment duration is shorter than necessary
C4.2 Treatment duration too long Treatment duration is longer than necessary
Medication
errors
C5 Mishaps or accidents during at any stage of drug handling, prescribing, transcribing,
dispensing and administering
C5.1 Inappropriate timing of administration and/or
dosing intervals
Error in the process of drug administration
C5.2 Drug underused/under-administered Error in the process of drug administration
C5.3 Drug overused/over-administered Error in the process of drug administration
C5.4 Drug not taken/administered at all Error in the process of drug administration
C5.5 Wrong drug taken/administered Error in the process of drug administration
C5.6 Drug abused (unregulated overuse) Self-explanatory
C5.7 Patient unable to use drug/drug form as directed Moved to category patient factor (C7.5)
C5.8a Prescribing error in decision making Error in deciding treatment
C5.8b Prescribing error in prescription writing Error in writing prescription
C5.9 Dispensing error Error in dispensing the prescribed drug
C5.10 Dilution error Error in the process of diluting a drug to its prescribed concentration
Drug supply C6.1 Prescribed drug not available Prescribed drug not available for use
C6.2 Difficulty in obtaining repeat prescription from
the community
There is a problem in obtaining repeat prescription(s) from the general practitioner (GP) or
the community pharmacy
Patient factor C7 The cause of the DRP can be related to the personality or behaviour of the patient
C7.1 Patient forgot to use/take drug Self-explanatory
C7.2 Patient used unnecessary drug Self-explanatory
C7.3 Patient took food that interacts with the
prescribed drug(s)
Self-explanatory
C7.4 Patient stored drug inappropriately Self-explanatory
C7.5 Patient refused to take the drug Self-explanatory
C7.6 Patient unable to use the drug Self-explanatory
C7.7 Patient (parent/carer) forgot to obtain repeat
prescription(s) from the community
Self-explanatory
C7.8 Poor understanding of treatment plan and
medications
Self-explanatory
Others C8 Other causes not specified above
C8.1 Poor medication reconciliation Discrepancies between the patient’s own drugs with those prescribed on admission.
Discrepancies between drugs planned to take home and the ones on discharge prescriptions
C8.2 Unwanted side effects Known undesirable effect of a drug other than the intended therapeutic effects
C8.3 Inappropriate drug administration site/route Wrong site and/or route for the prescribed drug
C8.4 Dependent on enteral feed tubes The patient is dependent on enteral feeding tubes for the administration of medicines
C8.5 Difficulty in obtaining information from the
general practitioner
Self-explanatory
C8.6 New dose not altered by the general practitioner Self-explanatory
NA not applicable
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Appendix 2
Table 6 Contributory factors for medication-related problems (MRPs) at the inpatient and outpatient renal clinic*
Inpatient (N1=399) Outpatient (N2=73)
Contributory factors for MRPs n (%) n (%)
C1 Drug selection 72 (18.0) 3 (4.1)
C1.7 Synergistic/preventive drug not prescribed 20 (5.0) 1 (1.4)
C1.9 No indication 13 (3.3) – –
C1.1 Inappropriate drug 10 (2.5) 1 (1.4)
C1.3 Inappropriate drug duplication 9 (2.3) 1 (1.4)
C1.4 Indication for drug not noticed 7 (1.8) – –
C1.5 Too many drugs unnecessarily for the same indication 6 (1.5) – –
C1.2 Inappropriate drug combination 5 (1.3) – –
C1.6 More cost-effective alternative available 1 (0.3) – –
C1.8 New indication 1 (0.3) – –
C2 Inappropriate drug form 7 (1.8) – –
C3 Drug dosage 97 (24.3) 4 (5.5)
C3.2 Dose too high 23 (5.8) 1 (1.4)
C3.1 Dose too low 17 (4.3) 2 (2.7)
C3.4 Dosage regimen too frequent 15 (3.8) – –
C3.7 Deterioration/improvement of disease state 10 (2.5) – –
C3.3 Dosage regimen not frequent enough 8 (2.0) – –
C3.6 Pharmacokinetic problem requiring dosage adjustment 8 (2.0) – –
C3.5 No therapeutic monitoring 3 (0.8) – –
C3.8 Dose difficult to measure 13 (3.3) – –
C4 Treatment duration 15 (3.8) – –
C4.2 Too long 13 (3.3) – –
C4.1 Too short 2 (0.5) – –
C5 Medication errors 181 (45.4) 1 (1.4)
C5.8a Prescribing error in decision making 104 (26.1) 1 (1.4)
C5.8b Prescribing error in prescription writing 72 (18.0) – –
C5.2 Drug over-administered 2 (0.5) – –
C5.1 Inappropriate timing of drug administration/dosing intervals 2 (0.5) – –
C5.9 Dispensing error 1 (0.3) – –
C6 Drug supply – – 8 (11.0)
C6.2 Problems with the process for obtaining repeat prescriptions from the community -– – 8 (11.0)
C7 Patient factors 1 (0.3) 31 (42.5)
C7.5 Refused to take medicines 1 (0.3) 6 (8.2)
C7.1 Forgot to take the drug – – 10 (13.7)
C7.7 Forgot to ask for refill prescription from community – – 1 (1.4)
C7.8 Poor understanding of treatment plan and medications 14 (19.2)
C8 Other factors 26 (6.5) 26 (35.6)
C8.2 Unwanted side effects 14 (3.5) 12 (16.4)
C8.1 Poor medication reconciliation 12 (3.0) – –
C8.4 Dependent on NG/PEG for medications – – 8 (11.0)
C8.5 Difficult to obtain information from GP – – 5 (6.8)
C8.6 New dose not altered by the GP – – 1 (1.4)
NG nasogastric, PEG percutaneous endoscopic gastrostomy
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